| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.windlasbiotech.com | |
| Market Cap | 1,154.42 Cr. | |
| Enterprise Value(EV) | 1,129.23 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 25.31 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 21.93 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 40.73 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 207.35 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 2.68 | Calculated using Price: 555.05 |
| Dividend Yield | 0.72 | Period Ending 2023-03 |
| No. of Shares Subscribed | 2.08 Cr. | 20,798,575 Shares |
| FaceValue | 5 | |
| About Windlas Biotech Ltd. | ||
| The company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world. | ||
| 1 Day |
|
+6.96% |
| 1 Week |
|
+1.48% |
| 1 Month |
|
+6.53% |
| 3 Month |
|
+15.18% |
| 6 Month |
|
+57.00% |
| 1 Year |
|
+120.63% |
| 2 Year |
|
+110.07% |
| 5 Year |
|
|
| 10 Year |
|
| 6 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 9.17 | 40.43 | 8.04 | 7.62 | 12.87 | 10.76 | |
| Return on Capital Employed (%) | 14.61 | 40.11 | 11.81 | 9.85 | 14.88 | 14.39 | |
| Return on Assets (%) | 3.87 | 21.75 | 5.1 | 4.91 | 9.7 | 8.39 |
| Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 125 | 194 | 210 | 199 | 395 | 402 | 416 | |
| Non Curr. Liab. | 21 | 8 | 3 | 4 | 0 | 3 | 3 | |
| Curr. Liab. | 143 | 96 | 125 | 93 | 94 | 121 | 149 | |
| Minority Int. | ||||||||
| Equity & Liab. | 289 | 298 | 338 | 296 | 489 | 527 | 568 | |
| Non Curr. Assets | 145 | 177 | 170 | 102 | 107 | 173 | 180 | |
| Curr. Assets | 144 | 120 | 168 | 194 | 382 | 354 | 388 | |
| Misc. Exp. not W/O | ||||||||
| Total Assets | 289 | 298 | 338 | 296 | 489 | 527 | 568 |
| Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 352 | 307 | 329 | 428 | 466 | 513 | 600 | |
| Other Income | 4 | 4 | 2 | 3 | 7 | 10 | 11 | |
| Total Income | 356 | 312 | 331 | 431 | 473 | 523 | 612 | |
| Total Expenditure | -313 | -269 | -287 | -373 | -414 | -453 | -528 | |
| PBIDT | 44 | 43 | 44 | 58 | 59 | 70 | 84 | |
| Interest | -6 | -5 | -3 | -1 | -1 | -1 | -1 | |
| Depreciation | -17 | -11 | -9 | -13 | -12 | -12 | -13 | |
| Taxation | -9 | -12 | -8 | -6 | -7 | -14 | -17 | |
| Exceptional Items | 50 | -22 | ||||||
| PAT | 11 | 64 | 16 | 16 | 38 | 43 | 53 | |
| Minority Interest | 0 | |||||||
| Share Associate | ||||||||
| Other Related Items | ||||||||
| Consolidated Net Profit | 11 | 64 | 16 | 16 | 38 | 43 | 53 | |
| Adjusted EPS | 7 | 35 | 9 | 9 | 17 | 20 | 25 |
| Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 35 | 19 | 25 | 11 | 9 | 61 | |
| Cash Fr. Inv. | -11 | -5 | -14 | -20 | -155 | -14 | |
| Cash Fr. Finan. | -26 | -6 | -5 | 1 | 130 | -44 | |
| Net Change | -2 | 7 | 5 | -8 | -15 | 3 | |
| Cash & Cash Eqvt | 7 | 13 | 18 | 16 | 1 | 4 |
|
Fri, 19 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Ananta Narayan Panda Designation: Company Secretary and Compliance Officer EmailId: cs@windlasbiotech.com Name of the Chief Financial Officer: Komal Gupta Designation: CEO and CFO EmailId: komal@windlasbiotech.com Date: 19/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Wed, 17 Apr 2024
Compliance Certificate In Terms Of Regulation 40 (9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Year Ended On March 31 2024 Compliance Certificate in terms of Regulation 40(9) of the SEBI LODR Regulations 2015 enclosed for the year ended March 31 2024. |
|||||||||||||||||||||
|
Sun, 14 Apr 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
| Fri, 19 Apr 2024 |
Closing Above Previous High
|
Close Within 52 Week High Zone
|
Making Higher Highs for 2 Days
|
Making Lower Lows for 2 Days
|
High Increase in 1 Month
|
